Department of Advanced Biomedical Sciences, Pathology Section Naples, Italy.
Department of Clinical Medicine and Surgery, Dermatology Section Naples, Italy.
Am J Clin Pathol. 2021 Aug 4;156(3):350-355. doi: 10.1093/ajcp/aqaa261.
Several studies suggested that CD30 expression is a favorable prognostic marker in transformed mycosis fungoides (tMF). However, evidence in this field is still unclear. This systematic review and meta-analysis aimed to evaluate the prognostic significance of CD30 in tMF.
Electronic databases were searched from their inception to June 2020 for all studies assessing the prognostic value of CD30 in tMF. Pooled hazard ratio (HR) for death was calculated; a P value less than .05 was considered significant. Inconsistency index (I2) was used to assess statistical heterogeneity among studies.
Seven studies with 323 patients were included. CD30 expression in tMF was significantly associated with a decreased hazard of death both on univariate (HR, 0.459; 95% confidence interval [CI], 0.319-0.660; P < .001) and multivariate analysis (HR, 0.503; 95% CI, 0.345-0.734; P < .001), and the statistical heterogeneity among studies was null in all analyses (I2 = 0%).
tMF cases with CD30 expression in large cells have a hazard of death two times lower than CD30-negative cases.
几项研究表明，CD30 表达是转化蕈样肉芽肿（tMF）的有利预后标志物。然而，该领域的证据仍不清楚。本系统评价和荟萃分析旨在评估 CD30 在 tMF 中的预后意义。
从数据库建立到 2020 年 6 月，检索评估 CD30 在 tMF 中预后价值的所有研究。计算死亡的合并危险比（HR）；P 值小于 0.05 被认为具有统计学意义。使用一致性指数（I2）评估研究之间的统计学异质性。
纳入了 7 项包含 323 例患者的研究。tMF 中 CD30 的表达与死亡风险降低显著相关，无论是在单因素（HR，0.459；95%置信区间[CI]，0.319-0.660；P < 0.001）还是多因素分析（HR，0.503；95% CI，0.345-0.734；P < 0.001）中，且所有分析中的研究间统计学异质性均为零（I2 = 0%）。
CD30 阳性大细胞 tMF 患者的死亡风险比 CD30 阴性患者低两倍。
